- 专利标题： Substituted inhibitors of menin-MLL and methods of use
-
申请号： US16082649申请日： 2017-03-15
-
公开(公告)号： US10781218B2公开(公告)日： 2020-09-22
- 发明人: Tao Wu , Liansheng Li , Yi Wang , Pingda Ren , Jolanta Grembecka , Tomasz Cierpicki , Szymon Klossowski , Jonathan Pollock , Dmitry Borkin
- 申请人： Kura Oncology, Inc. , The Regents of The University of Michigan
- 申请人地址： US CA San Diego US MI Ann Arbor
- 专利权人： KURA ONCOLOGY, INC.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- 当前专利权人： KURA ONCOLOGY, INC.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- 当前专利权人地址： US CA San Diego US MI Ann Arbor
- 代理机构： Wilson Sonsini Goodrich & Rosati
- 国际申请： PCT/US2017/022564 WO 20170315
- 国际公布： WO2017/161028 WO 20170921
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; C07D495/04 ; A61P35/00
摘要：
The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
公开/授权文献
- US20190092784A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE 公开/授权日：2019-03-28
信息查询
IPC分类:
